{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:41:55Z","timestamp":1781134915675,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jvir.2025.06.014","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:22:09Z","timestamp":1761121329000},"page":"1812-1819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients"],"prefix":"10.1016","volume":"36","author":[{"given":"Hongmin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2025.06.014_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2025.06.014_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jvir.2025.06.014_bib3","article-title":"Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma","volume":"2011","author":"Oliveri","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvir.2025.06.014_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2025.06.014_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camm\u00e0","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2025.06.014_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.06.014_bib7","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2025.06.014_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2025.06.014_bib9","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.transproceed.2012.07.006","article-title":"Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma","volume":"44","author":"de Ataide","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jvir.2025.06.014_bib10","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3748\/wjg.v28.i23.2561","article-title":"Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma","volume":"28","author":"Silk","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jvir.2025.06.014_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jfma.2021.07.003","article-title":"Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jvir.2025.06.014_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jvir.2025.06.014_bib13","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1002\/cam4.3937","article-title":"Association between pre-diagnostic serum albumin and cancer risk: results from a prospective population-based study","volume":"10","author":"Yang","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jvir.2025.06.014_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/2050640616673516","article-title":"Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"5","author":"Facciorusso","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.jvir.2025.06.014_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2025.06.014_bib16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/cancers10120516","article-title":"Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: stereotactic body radiotherapy versus sorafenib","volume":"10","author":"Shen","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2025.06.014_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2025.06.014_bib18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2025.06.014_bib19","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2025.06.014_bib20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/fon-2020-0162","article-title":"IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","volume":"16","author":"Hack","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jvir.2025.06.014_bib21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044325004361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044325004361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:45:44Z","timestamp":1761183944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044325004361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1051044325004361"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2025.06.014","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2025.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2025.08.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR, 2025","name":"copyright","label":"Copyright"}]}}